Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

This case study describes the development, implementation and review of a sustainable and culturally sensitive procedure for a hospital-funded discharge medicine subsidy for Aboriginal and Torres Strait Islander patients registered with the Closing the Gap (CTG) program discharging from a public hospital. A 7-day fully subsidised medication supply was approved to be offered to Aboriginal and Torres Strait Islander patients admitted under cardiac care teams, including cardiology and cardiothoracic surgery patients. Patients were offered the option of a 7-day supply free of cost to them or a full Pharmaceutical Benefits Scheme (PBS) supply if preferred. A general practitioner (GP) appointment was organised within 7 days of discharge to ensure patients received ongoing supply of their medications as well as timely clinical review after discharge. Over a 34-month period from September 2015 to June 2018, 535 Aboriginal and Torres Strait Islander patients were admitted to the hospital under cardiac care teams. Of these patients, 296 received a subsidised discharge medication supply with a total cost of A$6314.56 to the hospital over the trial period, with a mean cost of A$21.26 per discharge. The provision of subsidised medications through the CTG program has improved the continuity of care for Aboriginal and Torres Strait Islander patients. The culturally sensitive approach is well received and has allowed smooth transition back to the community. This site-specific and state-based funding model was found to be financially sustainable at a public hospital.

Citation

Scott Mitchell, Hayley Michael, Stephanie Highden-Smith, Vivian Bryce, Sean Grugan, Hua Bing Yong, Sonia Renouf, Tanya Kitchener, William Y S Wang. Culturally safe and sustainable solution for Closing the Gap-registered patients discharging from a tertiary public hospital. Australian health review : a publication of the Australian Hospital Association. 2020 Apr;44(2):200-204

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32192571

View Full Text